CBIO SEC Filing News — Crescent Biopharma, Inc.

Latest SEC filings for Crescent Biopharma, Inc. (CBIO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics…
Sector: Healthcare Industry: Biotechnology Market Cap: $459.1M
20
Total Filings
1
Bullish Classifications
10
Bearish Classifications
11
Insider Transactions
4
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for CBIO currently lean bearish. Of the 20 filing records displayed, 10 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
CBIO Filing Activity Snapshot 2026-06-23 — 2026-10-15
Insider Transactions (Form 4)
1 buy vs 10 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$12.38M
Fairmount Funds Management LLC (Director, 10% Owner) · 2026-07-20
853,450 shares · Form 4
Form 144 Notices
4
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Crescent Biopharma, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 10 open-market sale and 1 open-market purchase. 11 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×10
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Open-market purchase ×1
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider Lynch Ryan (See Remarks) sold 240 shares (~$4.3K)

Lynch Ryan, listed as See Remarks at CRESCENT BIOPHARMA, INC., reported an open-market sale of 240 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 240 $17.90 $4.3K
Filing: Form 4 (Insider Transaction) Insider: Lynch Ryan (See Remarks) Shares: 240 Est. Value: $4.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider Pinkas Jan (Chief Scientific Officer) sold 658 shares (~$11.8K)

Pinkas Jan, listed as Chief Scientific Officer at CRESCENT BIOPHARMA, INC., reported an open-market sale of 658 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 658 $17.90 $11.8K
Filing: Form 4 (Insider Transaction) Insider: Pinkas Jan (Chief Scientific Officer) Shares: 658 Est. Value: $11.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider Im Ellie Eunkyung (Chief Medical Officer) sold 623 shares (~$11.2K)

Im Ellie Eunkyung, listed as Chief Medical Officer at CRESCENT BIOPHARMA, INC., reported an open-market sale of 623 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 623 $17.90 $11.2K
Filing: Form 4 (Insider Transaction) Insider: Im Ellie Eunkyung (Chief Medical Officer) Shares: 623 Est. Value: $11.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider Scalzo Richard William (Chief Financial Officer) sold 568 shares (~$10.2K)

Scalzo Richard William, listed as Chief Financial Officer at CRESCENT BIOPHARMA, INC., reported an open-market sale of 568 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 568 $17.90 $10.2K
Filing: Form 4 (Insider Transaction) Insider: Scalzo Richard William (Chief Financial Officer) Shares: 568 Est. Value: $10.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider Bispham Barbara Harlin (See Remarks) sold 620 shares (~$11.1K)

Bispham Barbara Harlin, listed as See Remarks at CRESCENT BIOPHARMA, INC., reported an open-market sale of 620 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 620 $17.90 $11.1K
Filing: Form 4 (Insider Transaction) Insider: Bispham Barbara Harlin (See Remarks) Shares: 620 Est. Value: $11.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider Brumm Joshua T (Director, Chief Executive Officer) sold 9,447 shares (~$159.8K)

Brumm Joshua T, listed as Director, Chief Executive Officer at CRESCENT BIOPHARMA, INC., reported an open-market sale of 9,447 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,610 $17.90 $28.8K
S Open-market sale 7,837 $16.71 $131.0K
Filing: Form 4 (Insider Transaction) Insider: Brumm Joshua T (Director, Chief Executive Officer) Shares: 9,447 Est. Value: $159.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

CBIO insider McNeill Jonathan (President and COO) sold 4,570 shares (~$77.2K)

McNeill Jonathan, listed as President and COO at CRESCENT BIOPHARMA, INC., reported an open-market sale of 4,570 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 731 $17.90 $13.1K
S Open-market sale 3,839 $16.71 $64.1K
Filing: Form 4 (Insider Transaction) Insider: McNeill Jonathan (President and COO) Shares: 4,570 Est. Value: $77.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-07-20

CBIO insider Fairmount Funds Management LLC (Director, 10% Owner) bought 853,450 shares (~$12.38M)

Fairmount Funds Management LLC, listed as Director, 10% Owner at CRESCENT BIOPHARMA, INC., reported an open-market purchase of 853,450 CBIO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 853,450 $14.50 $12.38M
P Open-market purchase derivative · Pre-Funded Warrant (Right to Buy) 525,897 $14.50 $7.62M
Filing: Form 4 (Insider Transaction) Insider: Fairmount Funds Management LLC (Director, 10% Owner) Shares: 853,450 Est. Value: $12.38M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-23

CBIO insider Lynch Ryan (See Remarks) sold 465 shares (~$8.4K)

Lynch Ryan, listed as See Remarks at CRESCENT BIOPHARMA, INC., reported an open-market sale of 465 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 465 $17.99 $8.4K
Filing: Form 4 (Insider Transaction) Insider: Lynch Ryan (See Remarks) Shares: 465 Est. Value: $8.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-23

CBIO insider Pinkas Jan (Chief Scientific Officer) sold 1,288 shares (~$23.2K)

Pinkas Jan, listed as Chief Scientific Officer at CRESCENT BIOPHARMA, INC., reported an open-market sale of 1,288 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,288 $17.99 $23.2K
Filing: Form 4 (Insider Transaction) Insider: Pinkas Jan (Chief Scientific Officer) Shares: 1,288 Est. Value: $23.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-23

CBIO insider Scalzo Richard William (Chief Financial Officer) sold 1,112 shares (~$20.0K)

Scalzo Richard William, listed as Chief Financial Officer at CRESCENT BIOPHARMA, INC., reported an open-market sale of 1,112 CBIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,112 $17.99 $20.0K
Filing: Form 4 (Insider Transaction) Insider: Scalzo Richard William (Chief Financial Officer) Shares: 1,112 Est. Value: $20.0K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Crescent Biopharma, Inc. has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-17

CBIO Form 144 filed for proposed insider sale by Joshua T Brumm (9,013 shares) ~$154.8K

Joshua T Brumm filed a Form 144 with the SEC indicating intent to sell CBIO (CRESCENT BIOPHARMA, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Joshua T Brumm Shares: 9,013 Est. Value: $154.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-17

CBIO Form 144 filed for proposed insider sale by Jonathan McNeill (4,415 shares) ~$75.8K

Jonathan McNeill filed a Form 144 with the SEC indicating intent to sell CBIO (CRESCENT BIOPHARMA, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Jonathan McNeill Shares: 4,415 Est. Value: $75.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-16

CBIO Form 144 filed for proposed insider sale by Jonathan McNeill (804 shares) ~$15.1K

Jonathan McNeill filed a Form 144 with the SEC indicating intent to sell CBIO (CRESCENT BIOPHARMA, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Jonathan McNeill Shares: 804 Est. Value: $15.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-16

CBIO Form 144 filed for proposed insider sale by Joshua T Brumm (1,771 shares) ~$33.3K

Joshua T Brumm filed a Form 144 with the SEC indicating intent to sell CBIO (CRESCENT BIOPHARMA, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Joshua T Brumm Shares: 1,771 Est. Value: $33.3K
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Crescent Biopharma, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-15

CBIO filed 8-K — material company event

CRESCENT BIOPHARMA, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-30

CBIO filed 8-K — material company event

CRESCENT BIOPHARMA, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-15

CBIO filed 8-K — material company event

CRESCENT BIOPHARMA, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-14

CBIO filed 8-K — material company event

CRESCENT BIOPHARMA, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Crescent Biopharma, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

CBIO filed Quarterly Report (10-Q)

CRESCENT BIOPHARMA, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Crescent Biopharma, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CBIO. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CBIO SEC Filings

More Tools for CBIO

CBIO Full Stock Analysis CBIO Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CBIO analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CBIO stock analysis page.

CBIO Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer